This study is looking at whether an intravenous (IV) iron treatment called ferric derisomaltose can help people with chronic heart failure (a condition where the heart can't pump enough blood) who also have low iron levels. The main goal is to see if ferric derisomaltose can reduce the number of times people are hospitalized for worsening heart failure or die from heart-related problems. You may be able to join if you are 18 or older, have symptomatic heart failure with reduced pumping ability (ejection fraction 45% or less), and have low iron. Researchers will compare those who receive ferric derisomaltose to those who don't. The study aims to enroll 1900 participants, but its current recruitment status is unclear.

Study design

This is an interventional study where participants will be randomly assigned (like flipping a coin) to either receive ferric derisomaltose or no ferric derisomaltose, with 1900 participants planned.

What's involved

You will visit the study site 4-5 times and have 7 video or phone calls. All participants will receive standard medical care for their condition.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed from enrollment until 52 weeks (about one year) after the study begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.